Trifluperidol

Trifluperidol
Clinical data
Trade namesTriperidol
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
Identifiers
  • 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23F4NO2
Molar mass409.425 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1cccc(c1)C3(O)CCN(CCCC(=O)c2ccc(F)cc2)CC3
  • InChI=1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2 checkY
  • Key:GPMXUUPHFNMNDH-UHFFFAOYSA-N checkY

Trifluperidol is a typical antipsychotic of the butyrophenone chemical class. It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects. It is used in the treatment of psychoses including mania and schizophrenia. It was discovered at Janssen Pharmaceutica in 1959.[2][3]

Synthesis

[edit]
Thieme Patent (claim 9):[4] Precursor:[5] Sila analogue:[6]

The Grignard reaction between 1-benzyl-4-piperidone [3612-20-2] (1) and 3-bromobenzotrifluoride [401-78-5] (2) gives 1-benzyl-4-(3-(trifluoromethyl)phenyl)piperidin-4-ol, CID:12718203 (3). Catalytic hydrogenation removes the benzyl protecting group to give 4-[3-(trifluoromethyl)phenyl]-4-piperidinol [2249-28-7] (4). Alkylation with 4-Chloro-4'-fluorobutyrophenone [3874-54-2] (5) introduces the sidechain and hence completed the synthesis of Trifluperidol (6).

See also

[edit]

References

[edit]
  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Gallant DM, Bishop MP, Timmons E, Steele CA (September 1963). "A controlled evaluation of Trifluperidol: a new potent psychopharmacologic agent". Current Therapeutic Research, Clinical and Experimental. 5: 463–71. PMID 14065098.
  3. ^ Gallant DM, Bishop MP, Timmons E, Steele CA (November 1963). "Trifluperidol: a butyrophenone derivative". The American Journal of Psychiatry. 120 (5): 485–7. doi:10.1176/ajp.120.5.485. PMID 14051242.
  4. ^ GB895309 idem P. Adriaan J. Janssen, U.S. patent 3,438,991 (1969 to Res Lab Dr C Janssen Nv).
  5. ^ 彭响亮, CN 105439811  (2016 to Chengdu Zhongheng Huatie Technology Co Ltd).
  6. ^ Tacke, R., Nguyen, B., Burschka, C., Lippert, W. P., Hamacher, A., Urban, C., Kassack, M. U. (12 April 2010). "Sila-Trifluperidol, a Silicon Analogue of the Dopamine (D 2 ) Receptor Antagonist Trifluperidol: Synthesis and Pharmacological Characterization". Organometallics. 29 (7): 1652–1660. doi:10.1021/om901011t.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Trifluperidol&oldid=1244064366"